SCHEMBL16656264

SCHEMBL16656264

CC(=O)CN1CCN(CCCCC(=O)O)CCN(CC(=O)OC(C)(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.44
CYP1A2 P05177 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SIGMAR1 Q99720 3/20 0.35
CACNA1H O95180 1/20 0.35
DRD2 P14416 5/20 0.34
HTR1A P08908 1/20 0.33
HTR7 P34969 1/20 0.33
PLA2G10 O15496 1/20 0.33
PLA2G5 P39877 1/20 0.33
TACR1 P25103 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16656254 0.96 CYP1A2 (0.45) PAOXCYP1A2MAPK1SMN1; SMN2SIGMAR1
SCHEMBL8515417 0.93 PAOX (0.44) PAOXCYP1A2MAPK1SMN1; SMN2SIGMAR1
Bromide SCHEMBL5133205 0.92 CYP1A2 (0.42) PAOXCYP1A2MAPK1SMN1; SMN2SIGMAR1
SCHEMBL16656261 0.90 GLA (0.39) PAOXCYP1A2MAPK1SMN1; SMN2SIGMAR1
SCHEMBL16656258 0.88 PAOX (0.47) PAOXSMN1; SMN2SIGMAR1CACNA1HDRD2
Bromide SCHEMBL5132382 0.87 CYP1A2 (0.47) PAOXCYP1A2MAPK1SMN1; SMN2SIGMAR1
SCHEMBL10016097 0.84 HSD17B10 (0.38) SMN1; SMN2CACNA1HPLA2G10PLA2G5
SCHEMBL20678135 0.84 GLA (0.43) CYP1A2MAPK1SMN1; SMN2SIGMAR1CACNA1H
SCHEMBL15938241 0.84 GLA (0.43) CYP1A2MAPK1SMN1; SMN2SIGMAR1CACNA1H
SCHEMBL14680626 0.84 PLA2G10 (0.38) CYP1A2SMN1; SMN2CACNA1HPLA2G10PLA2G5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012604-B2 Triazanonane derivatives or pharmaceutically acceptable salt thereof for enhanced fluorine-18 labeling Snur & DB Foundation (KR) 2015-04-21 US disclosed